MATE1 Regulates Cellular Uptake and Sensitivity to Imatinib in CML Patients

Blood Cancer Journal - United States
doi 10.1038/bcj.2016.79
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CML: Langzeitresultate Zum Imatinib-Stopp

Im Focus Onkologie
2017English

The EUTOS Prognostic Score: Review and Validation in 1288 Patients With CML Treated Frontline With Imatinib

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Downregulation of Γ-Catenin Inhibits CML Cell Growth and Potentiates the Response of CML Cells to Imatinib Through Β-Catenin Inhibition

International Journal of Molecular Medicine
MedicineGenetics
2012English

Efficacy and Safety of Imatinib in Paediatric CML – A Single Centre Study

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2019English

Lonafarnib Reduces the Resistance of Primitive Quiescent CML Cells to Imatinib Mesylate in Vitro

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

A Novel BCR-Abl Splice Isoform Is Associated With the L248V Mutation in CML Patients With Acquired Resistance to Imatinib

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

EVI-1 Oncogene Expression Predicts Survival in Chronic-Phase CML Patients Resistant to Imatinib Treated With Second-Generation Tyrosine Kinase Inhibitors

Blood
BiochemistryImmunologyCell BiologyHematology
2010English

CXCR4 Up-Regulation by Imatinib Induces Chronic Myelogenous Leukemia (CML) Cell Migration to Bone Marrow Stroma and Promotes Survival of Quiescent CML Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

Acta Pharmacologica Sinica
MedicinePharmacology
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy